About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

NCT01511874·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

HanAll BioPharma Co., Ltd.

Age

20–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Male of 20 years or above
Subject with prostate cancer with TNM stage T2\~4NxMx
Blood testosterone concentration ≥ 100ng/dl
Bilirubin ≤ 1.5xULN, transaminase ≤ 2.5xULN
WHO ECOG performance status ≤ 2
Signed written informed consent

You may not be if

Hormone-Refractory Prostate cancer
Brain metastasis
Another primary malignant tumor except for prostate cancer
Other conditions which in the opinion of the investigator preclude enrollment into the study

The record

StatusCompleted

PhasePhase 4

Taking part42

StartedJan 2011

UpdatedSep 23, 2015

Conditions

Prostate Cancer

Where1

Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
Seoul, South Korea

Clareo Health | Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer